Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
70
FMS Quote, Financials, Valuation and Earnings
Last price:
$23.52
Seasonality move
:
1.38%
Day range:
$23.48 - $23.71
52-week range:
$22.05 - $30.46
Dividend yield:
3.47%
P/E ratio:
17.06x
P/S ratio:
0.63x
P/B ratio:
0.91x
Volume:
293.3K
Avg. volume:
513.9K
1-year change:
4.58%
Market cap:
$13.8B
Revenue:
$20.9B
EPS (TTM):
$1.38
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FMS
Fresenius Medical Care AG
|
$5.8B | $0.57 | 2.77% | 407.8% | $28.51 |
|
BNTX
BioNTech SE
|
$1.2B | $0.12 | -24.04% | -86.85% | $138.33 |
|
CVAC
CureVac NV
|
$25.1M | -$0.08 | 0.04% | -32.36% | $5.31 |
|
EVO
Evotec SE
|
$219.8M | -$0.01 | 17.8% | -75.1% | $5.4436 |
|
IFRX
InflaRx NV
|
$8.2K | -$0.14 | -74.55% | -16.09% | $11.24 |
|
IMTX
Immatics NV
|
$14.2M | -$0.45 | -81.87% | -704.25% | $18.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FMS
Fresenius Medical Care AG
|
$23.51 | $28.51 | $13.8B | 17.06x | $0.81 | 3.47% | 0.63x |
|
BNTX
BioNTech SE
|
$92.50 | $138.33 | $22.2B | 191.55x | $0.00 | 0% | 6.29x |
|
CVAC
CureVac NV
|
$4.16 | $5.31 | $936.7M | 5.82x | $0.00 | 0% | 11.56x |
|
EVO
Evotec SE
|
$2.9500 | $5.4436 | $1B | -- | $0.00 | 0% | 1.26x |
|
IFRX
InflaRx NV
|
$1.11 | $11.24 | $75.2M | -- | $0.00 | 0% | 342.97x |
|
IMTX
Immatics NV
|
$10.27 | $18.75 | $1.2B | 42.21x | $0.00 | 0% | 13.72x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FMS
Fresenius Medical Care AG
|
44.71% | 0.616 | 74.22% | 0.78x |
|
BNTX
BioNTech SE
|
1.31% | 1.267 | 1.22% | 6.78x |
|
CVAC
CureVac NV
|
3.87% | 1.835 | 3.39% | 1.84x |
|
EVO
Evotec SE
|
37.72% | 1.505 | 44.12% | 1.05x |
|
IFRX
InflaRx NV
|
2.1% | -0.453 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.78% | 2.023 | 1.86% | 6.97x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FMS
Fresenius Medical Care AG
|
$1.5B | $582M | 3.54% | 6.14% | 10.2% | $661M |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
CVAC
CureVac NV
|
$57.9M | -$11.6M | 19.52% | 20.55% | -18.33% | $31.6M |
|
EVO
Evotec SE
|
-$72.4K | -$59.7M | -11.62% | -17.7% | -31.17% | -$101.3M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
Fresenius Medical Care AG vs. Competitors
-
Which has Higher Returns FMS or BNTX?
BioNTech SE has a net margin of 6.7% compared to Fresenius Medical Care AG's net margin of -1.89%. Fresenius Medical Care AG's return on equity of 6.14% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital FMSFresenius Medical Care AG25.43% $0.55 $28.6B BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About FMS or BNTX?
Fresenius Medical Care AG has a consensus price target of $28.51, signalling upside risk potential of 22.09%. On the other hand BioNTech SE has an analysts' consensus of $138.33 which suggests that it could grow by 49.55%. Given that BioNTech SE has higher upside potential than Fresenius Medical Care AG, analysts believe BioNTech SE is more attractive than Fresenius Medical Care AG.
Company Buy Ratings Hold Ratings Sell Ratings FMSFresenius Medical Care AG1 3 1 BNTXBioNTech SE14 5 0 -
Is FMS or BNTX More Risky?
Fresenius Medical Care AG has a beta of 0.900, which suggesting that the stock is 10.034% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.295, suggesting its more volatile than the S&P 500 by 29.477%.
-
Which is a Better Dividend Stock FMS or BNTX?
Fresenius Medical Care AG has a quarterly dividend of $0.81 per share corresponding to a yield of 3.47%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 57.49% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FMS or BNTX?
Fresenius Medical Care AG quarterly revenues are $5.7B, which are larger than BioNTech SE quarterly revenues of $1.8B. Fresenius Medical Care AG's net income of $382.5M is higher than BioNTech SE's net income of -$33.5M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 17.06x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.63x versus 6.29x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FMSFresenius Medical Care AG0.63x 17.06x $5.7B $382.5M BNTXBioNTech SE6.29x 191.55x $1.8B -$33.5M
-
Which has Higher Returns FMS or CVAC?
CureVac NV has a net margin of 6.7% compared to Fresenius Medical Care AG's net margin of -5832.47%. Fresenius Medical Care AG's return on equity of 6.14% beat CureVac NV's return on equity of 20.55%.
Company Gross Margin Earnings Per Share Invested Capital FMSFresenius Medical Care AG25.43% $0.55 $28.6B CVACCureVac NV91.57% $1.41 $1.1B -
What do Analysts Say About FMS or CVAC?
Fresenius Medical Care AG has a consensus price target of $28.51, signalling upside risk potential of 22.09%. On the other hand CureVac NV has an analysts' consensus of $5.31 which suggests that it could grow by 27.96%. Given that CureVac NV has higher upside potential than Fresenius Medical Care AG, analysts believe CureVac NV is more attractive than Fresenius Medical Care AG.
Company Buy Ratings Hold Ratings Sell Ratings FMSFresenius Medical Care AG1 3 1 CVACCureVac NV1 3 0 -
Is FMS or CVAC More Risky?
Fresenius Medical Care AG has a beta of 0.900, which suggesting that the stock is 10.034% less volatile than S&P 500. In comparison CureVac NV has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.063%.
-
Which is a Better Dividend Stock FMS or CVAC?
Fresenius Medical Care AG has a quarterly dividend of $0.81 per share corresponding to a yield of 3.47%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 57.49% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FMS or CVAC?
Fresenius Medical Care AG quarterly revenues are $5.7B, which are larger than CureVac NV quarterly revenues of $63.3M. Fresenius Medical Care AG's net income of $382.5M is higher than CureVac NV's net income of $319.3M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 17.06x while CureVac NV's PE ratio is 5.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.63x versus 11.56x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FMSFresenius Medical Care AG0.63x 17.06x $5.7B $382.5M CVACCureVac NV11.56x 5.82x $63.3M $319.3M
-
Which has Higher Returns FMS or EVO?
Evotec SE has a net margin of 6.7% compared to Fresenius Medical Care AG's net margin of -26.29%. Fresenius Medical Care AG's return on equity of 6.14% beat Evotec SE's return on equity of -17.7%.
Company Gross Margin Earnings Per Share Invested Capital FMSFresenius Medical Care AG25.43% $0.55 $28.6B EVOEvotec SE-0.04% -$0.14 $1.5B -
What do Analysts Say About FMS or EVO?
Fresenius Medical Care AG has a consensus price target of $28.51, signalling upside risk potential of 22.09%. On the other hand Evotec SE has an analysts' consensus of $5.4436 which suggests that it could grow by 85.23%. Given that Evotec SE has higher upside potential than Fresenius Medical Care AG, analysts believe Evotec SE is more attractive than Fresenius Medical Care AG.
Company Buy Ratings Hold Ratings Sell Ratings FMSFresenius Medical Care AG1 3 1 EVOEvotec SE1 0 0 -
Is FMS or EVO More Risky?
Fresenius Medical Care AG has a beta of 0.900, which suggesting that the stock is 10.034% less volatile than S&P 500. In comparison Evotec SE has a beta of 1.821, suggesting its more volatile than the S&P 500 by 82.079%.
-
Which is a Better Dividend Stock FMS or EVO?
Fresenius Medical Care AG has a quarterly dividend of $0.81 per share corresponding to a yield of 3.47%. Evotec SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 57.49% of its earnings as a dividend. Evotec SE pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FMS or EVO?
Fresenius Medical Care AG quarterly revenues are $5.7B, which are larger than Evotec SE quarterly revenues of $191.5M. Fresenius Medical Care AG's net income of $382.5M is higher than Evotec SE's net income of -$50.3M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 17.06x while Evotec SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.63x versus 1.26x for Evotec SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FMSFresenius Medical Care AG0.63x 17.06x $5.7B $382.5M EVOEvotec SE1.26x -- $191.5M -$50.3M
-
Which has Higher Returns FMS or IFRX?
InflaRx NV has a net margin of 6.7% compared to Fresenius Medical Care AG's net margin of -51538.49%. Fresenius Medical Care AG's return on equity of 6.14% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital FMSFresenius Medical Care AG25.43% $0.55 $28.6B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About FMS or IFRX?
Fresenius Medical Care AG has a consensus price target of $28.51, signalling upside risk potential of 22.09%. On the other hand InflaRx NV has an analysts' consensus of $11.24 which suggests that it could grow by 912.95%. Given that InflaRx NV has higher upside potential than Fresenius Medical Care AG, analysts believe InflaRx NV is more attractive than Fresenius Medical Care AG.
Company Buy Ratings Hold Ratings Sell Ratings FMSFresenius Medical Care AG1 3 1 IFRXInflaRx NV5 2 0 -
Is FMS or IFRX More Risky?
Fresenius Medical Care AG has a beta of 0.900, which suggesting that the stock is 10.034% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.896%.
-
Which is a Better Dividend Stock FMS or IFRX?
Fresenius Medical Care AG has a quarterly dividend of $0.81 per share corresponding to a yield of 3.47%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 57.49% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FMS or IFRX?
Fresenius Medical Care AG quarterly revenues are $5.7B, which are larger than InflaRx NV quarterly revenues of $27.8K. Fresenius Medical Care AG's net income of $382.5M is higher than InflaRx NV's net income of -$14.3M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 17.06x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.63x versus 342.97x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FMSFresenius Medical Care AG0.63x 17.06x $5.7B $382.5M IFRXInflaRx NV342.97x -- $27.8K -$14.3M
-
Which has Higher Returns FMS or IMTX?
Immatics NV has a net margin of 6.7% compared to Fresenius Medical Care AG's net margin of -974.45%. Fresenius Medical Care AG's return on equity of 6.14% beat Immatics NV's return on equity of -25.21%.
Company Gross Margin Earnings Per Share Invested Capital FMSFresenius Medical Care AG25.43% $0.55 $28.6B IMTXImmatics NV-- -$0.49 $508.8M -
What do Analysts Say About FMS or IMTX?
Fresenius Medical Care AG has a consensus price target of $28.51, signalling upside risk potential of 22.09%. On the other hand Immatics NV has an analysts' consensus of $18.75 which suggests that it could grow by 82.57%. Given that Immatics NV has higher upside potential than Fresenius Medical Care AG, analysts believe Immatics NV is more attractive than Fresenius Medical Care AG.
Company Buy Ratings Hold Ratings Sell Ratings FMSFresenius Medical Care AG1 3 1 IMTXImmatics NV9 0 0 -
Is FMS or IMTX More Risky?
Fresenius Medical Care AG has a beta of 0.900, which suggesting that the stock is 10.034% less volatile than S&P 500. In comparison Immatics NV has a beta of 1.361, suggesting its more volatile than the S&P 500 by 36.134%.
-
Which is a Better Dividend Stock FMS or IMTX?
Fresenius Medical Care AG has a quarterly dividend of $0.81 per share corresponding to a yield of 3.47%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 57.49% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FMS or IMTX?
Fresenius Medical Care AG quarterly revenues are $5.7B, which are larger than Immatics NV quarterly revenues of $6.1M. Fresenius Medical Care AG's net income of $382.5M is higher than Immatics NV's net income of -$59.1M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 17.06x while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.63x versus 13.72x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FMSFresenius Medical Care AG0.63x 17.06x $5.7B $382.5M IMTXImmatics NV13.72x 42.21x $6.1M -$59.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
